Difference between revisions of "Combining-Valproic acid-Lamotrigine"

From Psychiatrienet
Jump to: navigation, search
(Created page with '{{Drugcombi | base = valproic acid | add = lamotrigine | info = * Valproic acid is principally metabolized by CYP2C9, CYP2C19, CYP2A6 and UDP-glucuronosyltransferases. Valproic ...')
 
Line 5: Line 5:
 
* Valproic acid is principally metabolized by CYP2C9, CYP2C19, CYP2A6 and UDP-glucuronosyltransferases. Valproic acid is an inhibitor of the enzymes CYP2C9, epoxide-hydroxylase and UDP-glucuronosyltransferases.  
 
* Valproic acid is principally metabolized by CYP2C9, CYP2C19, CYP2A6 and UDP-glucuronosyltransferases. Valproic acid is an inhibitor of the enzymes CYP2C9, epoxide-hydroxylase and UDP-glucuronosyltransferases.  
 
* Lamotrigine is principally metabolised by UDP-glucuronosyltransferases.
 
* Lamotrigine is principally metabolised by UDP-glucuronosyltransferases.
* This combination of drugs may have possible synergistic effects. However, the pharmacokinetic drug interactions will influence the plasma levels. Dose adaptation will be recommended for this combination.
+
* {{PossibleSynergisticEffects}}
 
| start =  
 
| start =  
 
* Lamotrigine generally has no significant effect on valproate levels, however caution is recommended.
 
* Lamotrigine generally has no significant effect on valproate levels, however caution is recommended.

Revision as of 13:29, 5 March 2010

Valproic acid
Type moodstabilizer
Group anticonvulsant
links
ATC-code N03AG01
PubChem 3121
PubMed acid%22 Valproic acid
Drugs.com valproic-acid
Kompas (Dutch) Valproic acid
Wikipedia Valproic acid
Lamotrigine
Type moodstabilizer
Group anticonvulsant
links
ATC-code N03AX09
PubChem 3878
PubMed Lamotrigine
Drugs.com lamotrigine
Kompas (Dutch) Lamotrigine
Wikipedia Lamotrigine

Adding lamotrigine to valproic acid.

Infobord.png General information
  • Valproic acid is principally metabolized by CYP2C9, CYP2C19, CYP2A6 and UDP-glucuronosyltransferases. Valproic acid is an inhibitor of the enzymes CYP2C9, epoxide-hydroxylase and UDP-glucuronosyltransferases.
  • Lamotrigine is principally metabolised by UDP-glucuronosyltransferases.
  • Valproic acid is principally metabolized by CYP2C9, CYP2C19, CYP2A6 and UDP-glucuronosyltransferases. Valproic acid is an inhibitor of the enzymes CYP2C9, epoxide-hydroxylase and UDP-glucuronosyltransferases.
  • Lamotrigine is principally metabolised by UDP-glucuronosyltransferases.
  • This combination of drugs may have possible synergistic effects. However, the pharmacokinetic drug interactions will influence the plasma levels. Dose adaptation will be recommended for this combination.
Eenrichtingbord.png Start lamotrigine
  • Lamotrigine generally has no significant effect on valproate levels, however caution is recommended.
  • Start lamotrigine at low dose and check valproate plasma level after 1 week. Change valproate dose if necessary. [5]
Letopbord.png Cave
  • Very slow titration of lamotrigine is recommended because reports of lamotrigine-related skin rashes. [6]


  1. 1.0 1.1 Farmacotherapeutisch Kompas; Toxicologie (dutch)
  2. 2.0 2.1 Farmacotherapeutisch Kompas - valproinezuur (dutch) Cite error: Invalid <ref> tag; name "ftk" defined multiple times with different content
  3. KNMP; Informatorium Medicamentorum 2023; Monografie "valproaat" (Dutch)
  4. Drugs.com lamotrigine
  5. Schalekamp T. et al, Interacties met Psychofarmaca, Stichting Health Base, Houten, 2002.
  6. Chang CC at al, Toxic epidermal necrolysis with combination lamotrigine and valproate in bipolar disorder. Prog Neuropsych. Biol Psychiatry. 2006 Jan;30(1):147-50
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.